NEW YORK, N.Y. – Theranos Inc. named a new vice-president in charge of regulatory issues and a new chief compliance officer weeks after federal regulators banned the company’s founder and CEO from owning or running a medical laboratory for two years.
The ban followed months of investigation by government testing regulators where they found a number of violations of federal testing standards at the blood-test company’s site. The action followed stories by The Wall Street Journal in which former employees said the company’s tests were unreliable.
Theranos named Dave Wurtz as vice-president of regulatory and quality and it named Daniel Guggenheim, as its chief compliance officer.
They report to CEO Elizabeth Holmes.